



**Ad Hoc Release**

Martinsried/Munich, Germany, May 02, 2007

## **MorphoSys Launches Share Capital Issuance**

MorphoSys AG (FSE: MOR; Prime Standard Segment; TecDAX) intends to place 652,188 new shares through an accelerated book building process to institutional investors in Europe and North America. The Management and Supervisory Boards of MorphoSys AG decided to increase the Company's equity capital against contribution in cash, excluding preemptive rights. Société Générale and WestLB AG will act as joint lead managers for this transaction, and are joined by Janney Montgomery Scott acting as selling agent in the USA.

MorphoSys intends to use the issue proceeds to further expand the Company's business activities mainly in the research antibody segment, operating under the brand AbD Serotec, and accelerate further growth of the Group.

END OF AD HOC ANNOUNCEMENT

***Important information:***

***This press release/ad-hoc announcement constitutes neither an offer to sell nor a solicitation to buy any securities.***

***This press release is not being issued in the United States of America and must not be distributed to U.S. persons (as defined in regulations S of the U.S. securities act of 1933, as amended ("Securities Act") or publications with a general circulation in the United States. This press release does not constitute an offer or invitation to purchase any securities in the United States. The securities of MorphoSys AG have not been registered under the securities act and may not be offered, sold or delivered within the United States or to U.S. persons absent from registration under or an applicable exemption from the registration requirements of the United States Securities Law.***

***This document is directed only at persons (I) who are outside the United Kingdom or (II) who have professional experience in matters relating to investment falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (The "order") or (III) who fall within article 49(2)(A) to (D) ("High net worth companies, Unincorporated Associations, etc.") of the order (all such persons together being referred to as "relevant persons"). Any person who is not a relevant person must not act or rely on this communication or any of its contents. Any investment or investment activity to which this communication relates is available only to relevant persons and will be engaged in only with relevant persons.***

#### About MorphoSys:

MorphoSys develops and applies innovative technologies for the production of synthetic antibodies, which accelerate drug discovery and target characterization. Founded in 1992, the Company's proprietary Human Combinatorial Antibody Library (HuCAL) technology is used by researchers worldwide for human antibody generation. The Company currently has licensing agreements and/or research collaborations with Astellas (Japan), Bayer-Schering (USA/Germany), Boehringer Ingelheim (Germany), Bristol-Myers Squibb (USA), Centocor Inc. (USA), Daiichi Sankyo & Co., Ltd. (Japan), GPC Biotech AG (Germany), Hoffmann-La Roche AG (Switzerland), ImmunoGen Inc. (USA), Merck & Co., Inc. (USA), Novartis AG (Switzerland), Novopiant GmbH (Germany), OncoMed Pharmaceuticals, Inc. (USA), Pfizer Inc. (USA), ProChon Biotech Ltd. (Israel), Schering-Plough (USA), Shionogi & Co., Ltd. (Japan), Xoma Ltd. (USA) and others. Additionally, MorphoSys is active in the antibody research market through its AbD Serotec business unit. The business unit was founded in 2003 for the purpose of exploiting the MorphoSys non-therapeutic antibody markets. MorphoSys' activities in the research antibody segment were significantly strengthened through the acquisition of the U.K. and U.S.-based Biogenesis Group in January 2005 and Serotec Group in 2006. For further information please visit the corporate website at: <http://www.morphosys.com/>

HuCAL<sup>®</sup> and HuCAL GOLD<sup>®</sup> are registered trademarks of MorphoSys AG

*Statements included in this press release which are not historical in nature are intended to be, and are hereby identified as, "forward-looking statements" for purposes of the safe harbour provided by Section 21E of the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The company cautions readers that forward-looking statements, including without limitation those relating to the company's future operations and business prospects, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements. Factors that may affect future operations and business prospects include, but are not limited to, clinical and scientific results and developments concerning corporate collaborations and the company's proprietary rights and other factors described in the prospectus relating to the company's recent public offering.*

#### **For more information, please contact MorphoSys:**

Dave Lemus  
Chief Financial Officer  
Tel: +49 (0) 89 / 899 27-439  
Fax: +49 (0) 89 / 899 27-5439  
[investors@morphosys.com](mailto:investors@morphosys.com)

Dr. Claudia Gutjahr-Löser  
Head of Corporate Communications  
Tel: +49 (0) 89 / 899 27-122  
Fax: +49 (0) 89 / 899 27-5122  
[gutjahr-loeser@morphosys.com](mailto:gutjahr-loeser@morphosys.com)

Mario Brkulj  
Manager Public Relations  
Tel: +49 (0) 89 / 899 27-454  
Fax: +49 (0) 89 / 899 27-5454  
[brkulj@morphosys.com](mailto:brkulj@morphosys.com)